Improving decision-making for lung cancer treatment
Shared Decision-Making Encounter Tool for Adjuvant Treatment of Lung Cancer: Randomized Control Trial
This study is testing a new communication tool to see if it helps patients with non-small cell lung cancer feel more satisfied and confident in their treatment choices when talking with their doctors.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Rochester, Minnesota) |
| Trial ID | NCT06122064 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates a shared decision-making communication tool designed to enhance the quality of treatment discussions between patients with non-small cell lung cancer and their clinicians. Patients are randomized into two groups: one receiving standard care and the other using the decision-making tool during their clinical encounters. The study aims to assess improvements in patient satisfaction and reductions in decisional conflict regarding treatment choices. Follow-up assessments will occur at 2 and 6 weeks post-intervention to evaluate the effectiveness of the tool.
Who should consider this trial
Good fit: Ideal candidates include adult patients aged 18 and older with stage II or higher non-small cell lung cancer who are eligible for adjuvant treatment.
Not a fit: Patients with significant barriers to informed consent or shared decision-making, such as dementia or severe sensory impairments, may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to better-informed patients and improved satisfaction with treatment decisions.
How similar studies have performed: Previous studies have shown that shared decision-making tools can enhance patient satisfaction and decision quality, indicating a promising approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * CLINICIANS: * All clinicians within identified departments participating are eligible (doctor of medicine \[MD\]/doctor of osteopathy \[DO\], fellows/residents, physician assistant \[PA\]/nurse practitioner \[NP\]) * PATIENTS: * Adult patients (\>= 18 years of age) * Appointments at Mayo Clinic in Rochester * Non-small cell lung cancer (NSCLC) stage \> 1B * Eligible by their oncologist for adjuvant treatment Exclusion Criteria: * Exclude patient with major barriers to provide written informed consent or to participate in shared decision-making (i.e., dementia, severe hearing or visual impairment)
Where this trial is running
Rochester, Minnesota
- Mayo Clinic in Rochester — Rochester, Minnesota, United States (Recruiting)
Study contacts
- Principal investigator: Konstantinos Leventakos, M.D., Ph.D. — Mayo Clinic in Rochester
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.